• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

Results

September 30, 2021

Encouraging Results of Ketamine Study

Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment TORONTO, ONTARIO Sept. 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective as a standalone antidepressant, versus as an adjunctive therapy. The study, which was conducted at the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia subsidiary, showed comparable clinical benefits (e.g., antidepressant effects and reduction in suicidal thoughts) in a large sample of 220 patients with treatment-resistant depression (TRD) who received intravenous (IV) ketamine infusions as a monotherapy, as compared with those receiving...